Amgen Inc. operates as one of the world's largest independent biotechnology companies, with a geographic footprint spanning approximately 100 countries. The company's commercial portfolio addresses critical medical needs across oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases. Key flagship products include Repatha for cholesterol management, Prolia and Xgeva for bone health, and Enbrel for inflammatory diseases, alongside a growing portfolio of biosimilars. Amgen leverages advanced biomanufacturing capabilities and artificial intelligence to accelerate drug discovery and clinical development. Its competitive position is anchored by its robust research and development pipeline, which focuses on protein-based therapeutics and genetic engineering to deliver innovative treatments.
